ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
09/23/201609:41:00Merck's Keytruda Finds Fast Entry Into China Via Medical-Tourism...
09/23/201608:00:00Merck to Hold Third-Quarter 2016 Sales and Earnings Conference...
09/20/201608:30:00Merck to Host Investor Teleconference to Discuss ESMO 2016 Highlights
09/20/201603:03:00Business Watch -- WSJ
09/19/201611:49:00Sanofi Files Suit Against Merck, Claiming Patent Infringements...
09/19/201608:30:00Sanofi Files Suit Against Merck
09/19/201608:14:00Sanofi Files Suit Against Merck on Patent Infringements -Update
09/19/201602:08:00Sanofi Files U.S. Suit Against Merck on Patent Infringements
09/15/201610:03:00Merck, Pfizer Diabetes Therapy Meets Late-Stage Study Goals
09/13/201622:30:00Obama Administration Makes Last-Ditch Push for Trade Vote
09/13/201609:00:00Merck Publishes 2015/2016 Global Corporate Responsibility Report
09/13/201603:15:00Merck's Consumer Health Business Presents New Purpose to Help...
09/12/201608:00:00New Biosimilar can Offer an Effective and Lower Cost Treatment...
09/12/201608:00:00Un nouveau produit biosimilaire peut offrir une option thérapeutique...
09/09/201608:00:00Merck to Participate at the Morgan Stanley Global Healthcare...
09/08/201603:04:00Business Watch -- WSJ
09/07/201614:42:00FDA to Review Merck Drug as First-Line Treatment for Lung Cancer
09/07/201608:50:00FDA to Review Merck's Keytruda as First-Line Treatment for Lung...
09/07/201606:45:00FDA Accepts Supplemental Biologics License Application, Assigns...
09/02/201609:42:00U.S. Hot Stocks: Hot Stocks to Watch

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad